Completed PHASE2 INTERVENTIONAL NCT00107874

Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section

Oral Misoprostol as a Second-line Alternative to Intravenous Oxytocin in Preventing Postoperative Blood Loss After Non-scheduled Cesarean Section: a Randomized, Double-blind, Placebo-controlled Trial

Sponsor: University Hospital, Basel, Switzerland

Conditions Postpartum Hemorrhage

Interventions misoprostol

Updated 6 times since 2017 Last updated: Apr 2, 2019 Started: Jan 31, 1999 Primary completion: Feb 28, 2002 Completion: Feb 28, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Postpartum Hemorrhage and is currently completed. University Hospital, Basel, Switzerland leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
May 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — May 2019 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Basel, Switzerland

Data source: University Hospital, Basel, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland